JIANGSU RECBIO TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.24 CNY | +0.54% |
|
+4.29% | -14.92% |
ETFs positioned on Jiangsu Recbio Technology Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.05% | 4 M€ | -27.92% |
Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.549
CNY
Average target price
11.99
CNY
Spread / Average Target
+40.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.92% | 567M | |
| -2.32% | 92.59B | |
| +3.16% | 41.43B | |
| -11.10% | 33.49B | |
| +55.64% | 25.06B | |
| -9.41% | 12.77B | |
| -12.25% | 11.58B | |
| -44.00% | 11.35B | |
| +4.42% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- 2179 Stock
- Funds and ETFs Jiangsu Recbio Technology Co., Ltd.
